false
0001448431
0001448431
2024-01-24
2024-01-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 24, 2024
OptimizeRx Corporation
(Exact name of registrant as specified in charter)
Nevada |
|
001-38543 |
|
26-1265381 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
260 Charles Street, Suite 302, Waltham, MA |
|
02453 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: 248.651.6568
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 Par Value |
|
OPRX |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Effective January 24, 2024, Gus Halas retired
from his position as Chairperson of the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”).
Effective January 24, 2024, the Board appointed Lynn O’Connor Vos, a director of the Company, to serve as Chairperson of the Board,
as well as a member of the Board’s Nominating & Governance Committee, Compensation Committee, and Audit Committee.
Effective January 24, 2024, the Board increased
the size of the Board to seven (7) members and, upon the recommendation of the Board’s Nominating & Governance Committee, appointed
Catherine M. Klema to serve as a director of the Company until the date of the Company’s 2024 annual meeting of stockholders and
until her successor is elected and qualified, except in the event of her earlier death, resignation or removal. The Board also appointed
Ms. Klema to serve as a member of the Audit Committee and the Compensation Committee of the Board.
As a non-employee director, Ms.
Klema will participate in the Company’s previously disclosed non-employee director compensation program, which includes, among other
things, an annual cash retainer of $40,000, an annual equity grant with a grant date value of approximately $150,000, an additional
annual cash retainer of $10,000 for serving as an Audit Committee Member and an additional
annual cash retainer of $5,000 for serving as a Compensation Committee Member.
Item
7.01 Regulation FD Disclosure.
On January 25, 2024, the Company issued a press
release announcing changes to the Board described in Item 5.02 above. A copy of the press release is furnished with this Current Report
on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 attached hereto
is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
OPTIMIZERX CORPORATION |
|
|
|
Date: January 26, 2024 |
By: |
/s/ Edward Stelmakh |
|
Name: |
Edward Stelmakh |
|
Title: |
Chief Financial Officer |
2
Exhibit 99.1
OptimizeRx Announces Strategic Board Changes
to Support Growth and Evolving Landscape
WALTHAM, MA. – January 25, 2024– OptimizeRx Corp. (the
“Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and
engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move
to further align with the company’s growth plans.
After nearly a decade of service, Gus Halas is retiring from his position
as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx’s success, and we extend our deepest
gratitude for his commitment and leadership.
Effective immediately, Lynn O’Connor Vos will assume the role
of Chairperson of the Board, succeeding Mr. Halas. Ms. Vos has been a seasoned and respected member of the OptimizeRx Board since 2015.
She brings a wealth of experience and expertise, in healthcare information technology, life sciences agencies, healthcare consulting,
and medical technology, to her new role and a deep understanding of the Company’s vision, making her the ideal candidate to lead
the Company into the next phase of growth.
“As we continue to evolve as a company focused on technology enabled
marketing services, we are excited to have Lynn move to Chair as Gus retires from the Board,” said Will Febbo, CEO of OptimizeRx.
“As a nurse and seasoned business leader, she deeply understands the needs of both healthcare providers and patients, making her
invaluable as we redefine how we engage with them. Lynn was, in fact, one of the main reasons why I joined OptimizeRx in 2015. Today,
I’m more excited than ever to continue working alongside her as we build a future where patient-centric, data driven solutions drive
care focused engagements and better health.”
“I’m thrilled to continue my journey with OptimizeRx to
provide guidance and oversight on the team’s growth and commercialization strategies,” stated Ms. Vos. “I am optimistic
about the Company’s ability to drive success, and I intend to support the team as they continue to be a very meaningful player with
their clients and partners.”
Further strengthening the Board’s expertise, OptimizeRx is pleased
to announce the appointment of Catherine M. Klema as a new member of the Board. Ms. Klema’s extensive experience in strategy, finance
and governance, and her board experience with health systems and pharmaceutical companies, will be instrumental in helping navigate the
evolving healthcare landscape.
“We warmly welcome Cathy to our Board of Directors,” said
Mr. Febbo. “Her deep understanding of the healthcare industry, combined with her proven track record of leadership and strategic
thinking, will be invaluable as we continue to grow and become highly relevant to digital commercialization for our clients.”
“I am honored to join OptimizeRx’s Board of Directors and
to contribute to its ongoing success,” said Ms. Klema. “I am impressed by the Company’s commitment to innovation and
its dedication to advance medication access and adherence and the impact this can have on improving patient lives. I look forward to working
with the Board and management team to help OptimizeRx achieve its mission of empowering the healthcare community through tech-enabled
communications solutions.”
These Board enhancements reflect OptimizeRx’s unwavering commitment
to offer life science companies more effective ways to deliver relevant information and services to healthcare providers and their patients
right at the point of care. With a sharp vision, solid financial profile, and a strengthened Board, OptimizeRx is positioned to capitalize
on the immense opportunities within the healthcare technology market and continue to deliver value to patients, healthcare professionals,
and investors.
About Lynn O’Connor Vos
Lynn Vos
was CEO of Grey Healthcare Group for 23 years, acquired by WPP in 2017, where she led nine acquisitions to grow the company from a regional
agency to a global enterprise with worldwide presence. Additionally, she has led medical device development organizations and healthcare
non-profits. She currently runs a consulting firm focused on advising healthcare startups and marketing organizations.
Ms. Vos is also currently the Chairperson of the board of Medisafe,
Inc, a patient adherence platform, and is a director of Aspira Women’s Health, Inc. (Nasdaq: AWH), a bio-analytical based company
focused on the development of gynecologic disease diagnostic tools, and Modular Medical, a development stage medical device company focused
on the design, development, and commercialization of innovative diabetes care technologies. She has held previous board appointments in
telecommunications and healthcare non-profits.
About Catherine M. Klema
Cathy Klema has
over 30 years of experience in the healthcare industry. Prior to establishing Nettleton Advisors, she served as Managing Director in
the Healthcare Investment Banking groups at SG Cowen Securities and Furman Selz LLC, where she advised clients on mergers and acquisitions,
divestitures, public offerings, and other strategic transactions. Ms. Klema is currently Chair of the Board of Managers of Quorum Health,
a leading health system with 12 hospitals across 10 states. She also serves on the Board of Trustees of Montefiore Health System, a prominent
academic health system in New York City. Previously, she was a Director of Allergan plc, a global pharmaceutical company, and Pharmaceutical
Product Development, Inc., a global contract research organization.
About OptimizeRx
OptimizeRx
provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers,
and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions
of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx
helps patients start and stay on their medications. For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”,
“expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”,
“designed”, “could”, “may”, “should”, “will” or other similar words and expressions
are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions,
projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including,
without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected
Adjusted EBITDA, expected adjusted EBITDA margin and prospects. These forward-looking statements are based on the Company’s current
expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any
intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events,
or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some
of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated
by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include,
but are not limited to, any synergies and other anticipated benefits of the Medicx merger may not be realized or may take longer than
anticipated to be realized; the risk that the integration of OptimizeRx and Medicx will be more costly or difficult than expected; the
effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact:
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Media Relations Contact
Dilma Bennett, Media Relations Manager
dbennett@optimizerx.com
Investor Relations Contact
Ashley Robinson - LifeSci Advisors, LLC
arr@lifesciadvisors.com
3
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From May 2024 to Jun 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Jun 2023 to Jun 2024